Today's CAR T Options in Multiple Myeloma Care with Luciano Costa, MD, UAB
Oct 27, 2023
auto_awesome
Dr. Luciano Costa discusses CAR T therapy in multiple myeloma, including availability improvements, testing in earlier lines of therapy, side effects, new targets, combo CAR Ts, maintenance therapy, open clinical trials, and new CAR T variants. The podcast delves into the significance of CAR-T therapy, advancements in FDA-approved drugs, ongoing clinical trials, maintenance therapy debates, and the importance of early access to CAR-T clinical trials in myeloma treatment.
CAR-T therapy demonstrates high efficacy in heavily relapsed myeloma patients, with response rates up to 90%, surpassing traditional treatments.
Exciting developments in CAR-T therapy involve targeting new antigens, exploring dual-target CAR-Ts, and utilizing off-the-shelf allogeneic CAR-Ts.
Patient involvement in clinical trials for CAR-T combinations and maintenance therapies enhances treatment outcomes and drives advancements in myeloma care.
Deep dives
Introduction of Healthy 2.0 Initiatives
Healthy 2.0 introduces three pillars of support for myeloma patients: personalized lifetime support and education, meaningful patient-to-patient connections, and a powerful patient data portal known as Healthy 3 Cure Hub. The initiative aims to invite over 25,000 patients to participate in the Cure Hub and raise $5 million towards myeloma research by 2025.
CAR-T Therapy Overview
CAR-T therapy utilizes T cells genetically modified to target unique markers on myeloma cells. The therapy has shown high response rates in leukemia and lymphoma, leading to its application in multiple myeloma. Currently, CAR-T therapies like Abecma and Carvyque are FDA approved and have shown significant efficacy in heavily relapsed myeloma patients.
Comparing CAR-T Response Rates
Traditional myeloma treatments like Daratumumab or Carfilzomib typically yield response rates of 20-30%. In contrast, CAR-T therapies have shown response rates ranging from the high 70s to 90%, making them transformative options for patients. The quick onset of response and potential for long-term remission distinguish CAR-T as a highly effective therapy in myeloma.
Future of CAR-T Therapy
Exciting developments in CAR-T therapy include targeting new antigens like GPRC5D and CD19, exploring dual-target CAR-Ts, utilizing allogeneic CAR-Ts to provide off-the-shelf treatments, and investigating maintenance therapies post-CAR-T. The integration of bi-specific antibodies after CAR-T failure shows promise as a follow-up therapeutic strategy with efficient response rates.
Clinical Trials and Maintenance Therapy
Ongoing clinical trials assess the effectiveness of combinations with bi-specific antibodies, allogeneic CAR-Ts, and maintenance therapies to enhance CAR-T outcomes. Proactive patient engagement in clinical trials offers early access to cutting-edge therapies, fostering advancements in myeloma treatment and paving the way for personalized and impactful care.
Caller Interaction and Future Directions
Caller questions highlighted interest in allogeneic CAR-T timelines and post-CAR-T treatments. Dr. Costa emphasized the evolving landscape of myeloma therapies, including the potential for a multi-pronged approach with bi-specific antibodies and the importance of clinical trials in advancing the field. The conversation underscored a collaborative effort between patients, clinicians, and researchers to leverage innovative strategies for improved myeloma care.
CAR T therapy is a highly effective treatment for myeloma patients, even in highly relapsed multiple myeloma. In today's show we will hear from Luciano Costa, MD of the University of Burmingham who will do a deep dive into CAR T therapy in multiple myeloma to discuss how CAR T availability is improving, how CAR T is being tested in earlier lines of therapy, side effects to consider, new CAR T targets, combo CAR Ts, maintenance therapy post-CAR T, open CAR T clinical trials and various new forms CAR T variants like NK CAR Ts. Join us for this important show on one of the most impressive therapies ever developed in myeloma!
Thanks to our episode sponsor,
Menarini Silicon Biosystems
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode